Our strategy

Infectious diseases are a major cause of illness and death throughout the world. The number of infectious outbreaks is increasing for many reasons: higher population density raises exposure to infectious agents, an aging population is more susceptible to infection, and a rise in global travel boosts the potential for spreading diseases across borders. In addition, natural disasters can have a devastating impact on sanitation, hygiene, infrastructure and healthcare facilities.

At Crucell, we are dedicated to saving lives and preventing illness around the world. We focus strongly on unmet medical needs in developing countries, where infectious diseases exert their greatest toll. At the same time, we work to protect travelers and vulnerable groups living in industrialized countries.

We target major health threats that demand innovative solutions, striving to lead rather than follow. We focus on infectious diseases because these pose an increasingly serious threat to the health of people worldwide—and we have the expertise to make a real difference in this disease area.

The combination of our scientific know-how, innovative technologies and quality products positions Crucell to become a major player in the biopharmaceutical arena.

Our strategy is based on three business drivers

1. A strong reseach and development (R&D) pipeline with promising products in a range of major disease areas. Read more...
2. Cutting-edge technologies that enable the discovery, development and production of biopharmaceutical products. These proprietary technologies drive in-house innovation and generate licensing revenue. Read more...
3. A broad range of marketed vaccine products that together combat 12 major infectious diseases. Read more...

Our competitive edge

Crucell’s proprietary technologies offer unique advantages for biopharmaceutical innovation. This competitive edge is exemplified by our PER.C6® technology, which is ideally suited to the manufacture of vaccines and therapeutic proteins such as antibodies. Compared to traditional production platforms, PER.C6® human cell-line technology provides much higher yields at lower cost, as well as safety advantages.

 

The combination of scientific know-how, innovative technologies and quality products positions Crucell to become a major player in the biopharmaceutical arena.

Partners and licensees

In addition to our own R&D activities, we have strategic partnerships with several leading healthcare companies, such as Johnson & Johnson, DSM Biologics, Merck, Novartis and sanofi pasteur. Through these agreements, our technologies play a vital role in the development of a vast number of vaccines and antibody products. Read more...